← Back to Search

Embolization Device

Citadel Embolization Device for Aneurysm

N/A
Recruiting
Led By Ansaar Rai, MD
Research Sponsored by Stryker Neurovascular
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aneurysm size is between 6-12 mm
Has a single, unruptured or ruptured target intracranial aneurysm that is suitable for endovascular treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-procedure
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of a new device to treat aneurysms.

Who is the study for?
This trial is for adults aged 18-80 with a specific type of brain aneurysm that's wide-necked and saccular, measuring 6-12 mm. Participants must be stable if the aneurysm has ruptured (with a low Hunt & Hess Score) and agree to follow study procedures. Exclusions include pregnancy, other ongoing studies affecting outcomes, previous treatment of the target aneurysm, planned future treatments within a year, certain health conditions like coagulopathy or significant vessel disease.Check my eligibility
What is being tested?
The Citadel Embolization Device Study tests Stryker Neurovascular's new device designed for treating wide-neck intracranial aneurysms when used alongside Target Detachable Coils. The goal is to evaluate its safety and effectiveness in managing these complex cases.See study design
What are the potential side effects?
While not explicitly listed in the provided information, typical side effects from embolization devices may include reactions to contrast agents used during the procedure such as nausea or rash; bruising or bleeding at the catheter insertion site; clotting issues; and potential risks associated with endovascular treatments like stroke.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My aneurysm is between 6-12 mm in size.
Select...
I have one brain aneurysm that can be treated without open surgery.
Select...
My brain aneurysm ruptured but I am neurologically stable.
Select...
I am between 18 and 80 years old.
Select...
My aneurysm is wide-necked and either at a branching point or on the side of a vessel.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Effectiveness Endpoint of this study is adequate aneurysm occlusion without retreatment or significant parent artery stenosis (>50% stenosis).
Primary Safety Endpoint is stroke-related neurologic death, or major ipsilateral or disabling stroke in the territory supplied by the treated artery
Secondary outcome measures
Secondary Safety Endpoint of this study is any stroke event occurring through 12 months post-procedure, where a stroke event is defined as per what is noted in the description.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Citadel Embolization DeviceExperimental Treatment1 Intervention
The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for wide-neck aneurysms include endovascular techniques such as coil embolization and the use of embolization devices like the Citadel Embolization Device. These treatments work by inserting coils or other embolic materials into the aneurysm sac through a catheter, which induces clot formation and blocks blood flow into the aneurysm. This prevents the aneurysm from growing or rupturing. For wide-neck aneurysms, specialized devices are often used to ensure that the coils remain in place and to provide additional support to the aneurysm walls. This is crucial for patients because wide-neck aneurysms are more challenging to treat due to their shape and size, and these advanced techniques help to reduce the risk of complications and improve outcomes.

Find a Location

Who is running the clinical trial?

Stryker NeurovascularLead Sponsor
35 Previous Clinical Trials
12,589 Total Patients Enrolled
Ansaar Rai, MDPrincipal InvestigatorWest Virginia University
2 Previous Clinical Trials
548 Total Patients Enrolled

Media Library

Citadel Embolization Device (Embolization Device) Clinical Trial Eligibility Overview. Trial Name: NCT04057352 — N/A
Wide-neck Aneurysms Research Study Groups: Citadel Embolization Device
Wide-neck Aneurysms Clinical Trial 2023: Citadel Embolization Device Highlights & Side Effects. Trial Name: NCT04057352 — N/A
Citadel Embolization Device (Embolization Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04057352 — N/A
~43 spots leftby Jun 2026